Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ('SiteOne'), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, today announced a definitive agreement for Lilly to acquire SiteOne.

礼来公司(NYSE: LLY) 和SiteOne Therapeutics, Inc.，SiteOne是一家私人生物技术公司，致力于开发钠通道小分子抑制剂以治疗疼痛和其他神经元过度兴奋性疾病，该公司今天宣布与礼来达成最终收购协议。

The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being studied for the treatment of pain. STC-004 may represent a next-generation, non-opioid treatment for patients suffering from chronic pain.

该交易包括STC-004，一种处于第二阶段准备就绪的Nav1.8抑制剂，正在研究用于治疗疼痛。STC-004可能代表了一种新一代的、非阿片类的慢性疼痛治疗方法。

'The global burden of chronic pain continues to increase, and an effective non-opioid treatment remains elusive,' said Mark Mintun, Lilly group vice president

“全球慢性疼痛的负担持续增加，有效的非阿片类治疗仍然难以捉摸，”礼来公司副总裁马克·明顿表示。

Neuroscience Research

神经科学研究

and Development. 'Lilly is eager to continue the development of STC-004 with the outstanding SiteOne team as part of our efforts to advance novel, addiction-free pain therapies. Innovation in pain management is critical to address the unmet needs of millions of patients around the world.'

和发展。'Lilly渴望与优秀的SiteOne团队继续开发STC-004，作为我们推进无成瘾新型疼痛疗法的努力的一部分。疼痛管理的创新对于满足全球数百万患者未满足的需求至关重要。'

Under the terms of the agreement, Lilly will acquire SiteOne and SiteOne shareholders could receive up to $1.0 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain regulatory and commercial milestones.

根据协议条款，礼来公司将收购SiteOne公司，SiteOne公司的股东可获得高达10亿美元的现金，其中包括首付款以及在实现某些监管和商业里程碑后的后续付款。

'At SiteOne, we've spent more than a decade advancing a vision to deliver safer, more effective, non-opioid therapies for patients suffering from pain and other sensory hyperexcitability disorders,' said

“在SiteOne，我们花费了十多年的时间推进一种愿景，即为遭受疼痛和其他感觉过敏性疾病折磨的患者提供更安全、更有效的非阿片类疗法，”

John Mulcahy

约翰·穆尔卡希

, Ph.D., chief executive officer and cofounder of

，博士，首席执行官兼创始人之一

SiteOne Therapeutics

SiteOne Therapeutics

. 'Lilly shares our deep commitment to scientific rigor, innovation, and patient-centered drug development. We believe their global capabilities and neuroscience leadership will accelerate our efforts to realize the full potential of STC-004 and our broader platform. This acquisition reflects the expertise and dedication of the SiteOne team and marks an exciting new chapter in our mission to transform pain treatment.'.

“礼来与我们一样，对科学严谨性、创新和以患者为中心的药物开发有着深刻的承诺。我们相信，他们的全球能力和神经科学领导地位将加速我们实现STC-004及更广泛平台的全部潜力的努力。此次收购体现了SiteOne团队的专业知识和奉献精神，并标志着我们变革疼痛治疗使命中令人兴奋的新篇章。”

The transaction is subject to customary closing conditions. Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance..

该交易受惯例成交条件的约束。礼来公司将在交易完成时根据公认会计原则（GAAP）确定此交易的会计处理方法。此后，该交易将反映在礼来的财务结果和财务指引中。

For Lilly,

致莉莉，

J.P. Morgan Securities LLC

摩根大通证券有限责任公司

is acting as exclusive financial advisor and

担任独家财务顾问并

Jones Day

琼斯·戴律师事务所

is acting as legal counsel. For SiteOne,

正在担任法律顾问。对于SiteOne，

Centerview Partners LLC

森特里维尤合伙人有限责任公司

is acting as exclusive financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP and

担任独家财务顾问，世达律师事务所（Skadden, Arps, Slate, Meagher & Flom LLP）和

Cooley LLP

高盖茨律师事务所

are acting as legal counsel.

正在担任法律顾问。

About SiteOne Therapeutics

关于SiteOne Therapeutics

SiteOne Therapeutics is a clinical-stage biopharmaceutical company advancing a novel class of highly selective small molecule inhibitors targeting Nav1.7, Nav1.8, and other ion channels to treat pain, cough and other conditions involving hyperexcitability of the peripheral nervous system. Since its inception, SiteOne has been dedicated to the development of safe and effective pain therapeutics without the significant addiction potential and side effects of opioids.

SiteOne Therapeutics是一家处于临床阶段的生物制药公司，正在推进一类新型的高度选择性小分子抑制剂的研发，这些抑制剂靶向Nav1.7、Nav1.8和其他离子通道，用于治疗疼痛、咳嗽以及涉及外周神经系统过度兴奋的其他疾病。自成立以来，SiteOne一直致力于开发安全有效的止痛疗法，避免阿片类药物显著的成瘾潜力和副作用。

The company is also advancing additional novel drug candidates that exhibit precise selectivity for individual ion channel subtypes to treat other sensory hyperexcitability disorders such as chronic cough and chronic ocular surface pain. For more information, visit .

该公司还在推进其他新型药物候选物，这些候选物对个别离子通道亚型表现出精确的选择性，用于治疗其他感觉过度兴奋性疾病，如慢性咳嗽和慢性眼表疼痛。欲了解更多信息，请访问。

About Lilly

关于Lilly

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases.

礼来是一家医药公司，将科学转化为治愈之力，以改善世界各地人们的生活。近150年来，我们一直在开创改变生命的发现，如今我们的药物帮助了全球数千万人。通过利用生物技术、化学和基因医学的力量，我们的科学家正在加速推进新的发现，以解决一些全球最重要的健康挑战：重新定义糖尿病护理；治疗肥胖症并遏制其最具破坏性的长期影响；推动对抗阿尔茨海默病的斗争；为一些最严重的免疫系统疾病提供解决方案；并将最难治疗的癌症转化为可管理的疾病。

With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit .

每迈向更健康的世界一步，我们都受到一个目标的激励：让数百万人的生活更美好。这包括开展反映世界多样性的创新临床试验，并努力确保我们的药品可及且价格合理。欲了解更多信息，请访问。